Citius Oncology (CTOR) Common Equity (2021 - 2026)

Citius Oncology's Common Equity history runs 6 years deep, the most recent figure standing at $35.3 million for Q1 2026.

• In Q1 2026, Common Equity fell 1.05% year-over-year to $35.3 million; the TTM figure through Mar 2026 stood at $35.3 million (down 1.05% YoY), while the FY2025 annual figure was $44.9 million, down 2.76% from the prior year.
• Common Equity was $35.3 million for Q1 2026 at Citius Oncology, down from $58.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $58.4 million in Q4 2025 to a low of -$1968.0 in Q2 2023.
• Historically, Common Equity has averaged $27.7 million across 5 years, with a median of $32.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Common Equity retreated 29.59% in 2023, then surged 865489.28% in 2024.
• A 5-year view of Common Equity shows it stood at $345508.0 in 2022, then jumped by 6477.35% to $22.7 million in 2023, then soared by 81.69% to $41.3 million in 2024, then soared by 41.47% to $58.4 million in 2025, then sank by 39.62% to $35.3 million in 2026.
• The last three Common Equity figures came in at $35.3 million (Q1 2026), $58.4 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.